@article{f48daa22a849418587751ee41ffd0318,
title = "Evolution of androgen deprivation therapy",
abstract = "The androgen signalling axis is critical for the development and progression of prostate cancer. Therefore, the mainstay treatments for metastatic disease are hormonal manipulations aimed at reducing androgen levels and/or blocking the androgen receptor, collectively termed androgen deprivation therapy. This review will discuss the evolution of androgen deprivation therapy since it was instigated more than 70 years ago, and outline the key mechanisms underlying its inevitable failure. We will also briefly introduce potential new androgen signalling-targeted therapies in clinical development.",
author = "Raj, {Ganesh V.} and Selth, {Luke A.} and Day, {Tanya K.} and Tilley, {Wayne D.}",
note = "Funding Information: Funding This work was supported by: the US Department of Defense Prostate Cancer Research Program (Transformative Impact Award W81XWH-13-2-0093 to L.A.S., G.V.R. and W.D.T.); the Prostate Cancer Foundation of Australia/Cancer Australia/Movember (Grant IDs 1012337 and 1043482; W.D.T. and L.A.S.); Prostate Cancer Foundation of Australia/Movember Revolutionary Team Award (W.D.T. and L.A.S.); the Ray and Shirl Norman Cancer Research Trust (to L.A.S. and W.D.T.); and a Young Investigator Award from the Prostate Cancer Foundation (L.A.S.). The Adelaide Prostate Cancer Research Centre is supported by an establishment grant from the PCFA (Grant ID 2011/0452; W.D.T., G.V.R. and L.A.S.).",
year = "2015",
month = nov,
language = "English (US)",
volume = "39",
pages = "189--194",
journal = "Cancer Forum",
issn = "0311-306X",
publisher = "The Cancer Council Australia",
number = "3",
}